Drugs / KD-025 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04550663 | Sep 2020 → Sep 2022 | colorectal cancer, glioma, hepatocellular carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KD-025 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04550663 ↗ |
| Modality | Cell therapy | “NKG2D-based CAR-T cells infusion” NCT04550663 ↗ |